Subject Index. Breastfeeding, self-monitoring of blood glucose 56

Size: px
Start display at page:

Download "Subject Index. Breastfeeding, self-monitoring of blood glucose 56"

Transcription

1 Subject Index Animas Vibe 86, 130 Artificial pancreas clinical studies inpatient studies outpatient studies outcome assessment 182, 183 technology 180, 181 telemedicine 182 components glucose sensor 167, 168 insulin administration routes 168, 169 control algorithm 170, 171 fuzzy-logic controllers 171 model predictive control , multimodular control 173 physiology-inspired controller 171 proportional-integral-derivative control 171, 179, 183 glucagon infusion 169 historical perspective 166, 167 meal announcement by patient 169 pramlintide infusion 169 preclinical testing 174, 175 prospects 183, 185 sensors other than glucose 170 Aspart, pregnancy use 19 ASPIRE study 159, 160 Athletes, real-time continuous glucose monitoring in diabetes 120, 121 Automated bolus calculator 212, 213 Best Information through Regional Outcomes 247 Biostator 167 Breastfeeding, self-monitoring of blood glucose 56 Clarke error grid analysis, glucose monitor accuracy assessment 115 Continuous glucose monitoring, see also Real-time continuous glucose monitoring advantages 88, 89 algorithms for calculating insulin delivery artificial pancreas, see Artificial pancreas data analysis 93, 94 disadvantages frequency of sensing 135, 254 historical perspective Abbott 86 Cygnus 85 Dexcom 85, 86 Medtronic 83 85, 113 hypoglycemia prevention 252, 253 mechanisms 154, 155 novel uses dead-in-bed syndrome 90 remote monitoring sleep eating 89 professional versus real-time systems 82, 83, quality of life 253, 254 sensor advances fluorescence-based sensors 95, 96 implantable glucose sensors 94, 95 intraperitoneal sensors 95 noninvasive sensors 96 systems 81, 82 technical aspects 260

2 accuracy 115, 116 calibration 114, 115 type 2 diabetes use 89 Continuous intraperitoneal insulin infusion advantages 201 adverse events anti-insulin antibodies 204, 205 implantation site 202 underdelivery 203, 204 artificial pancreas 168 catheter requirements 196, 197 clinical experience 193, 194 feasibility studies historical perspective indications 206, 207 insulin pharmacokinetics and pharmacodynamics 192, 193 preparations 194, 195 pump requirements 195, 196 rationale Continuous subcutaneous insulin infusion advantages 251 age of patients 134, 135 basal rate and bolus calculation 129, 130 clinical efficacy and safety diabetic ketoacidosis 132 glycemic control 131 hypoglycemia 131, 132, 252 long-term complications 132 pregnant type 1 diabetes patients 133 quality of life 132 cost-effectiveness 138 disadvantages 137 education of patients 134 general considerations 152, 153 historical perspective 128, 129 indications 138, 139 management in intensive and nonintensive treatment 8, 9 medical and surgical ward patients 40 multiple daily insulin comparison 7, 8 overview 7 pediatric diabetes dropouts 146 evidence-based medicine 144 guidelines 145 indications 144, 145 neonatal diabetes 144 sensor-augmented pump, see Sensoraugmented pump prospects 139 quality of life 253 self-monitoring of blood glucose 54, 55 technology and comparison of pumps 129, 130 Critical care, see Intensive care unit DAFNE study 211 Dead-in-bed syndrome, continuous glucose monitoring 90 Detemir pregnancy use 20 Dextrostix 47, 63 Diabecare R 130 Diabeo system decision-support systems Télédiab 1 study TELESAGE study 222, 223 Diabetes Audit and Research in Tayside Study 239 Diabetes Control Complications Trial blood glucose targets to prevent vascular events 4, 5, 151 historical perspective 1, 2 microangiopathy and glucose control effects 2 4 self-monitoring of blood glucose 48 Diabetes Insulin Guidance System 213, 214 Diabetes Interactive Diary clinical studies overview 227, 228 prospects 232, 233 rationale 226, 227 Diabetes registers architecture of integrated registers best practices functions 236, 237 information exchange challenges prospects Diabetic ketoacidosis studies 132 self-monitoring of blood glucose guidelines 52, 53 DiaPort 168, 192, 207 Driving, hypoglycemia risks 53, 54 Subject Index 261

3 Enlite 116 ENTRED 211 Error grid analysis, see Clarke error grid analysis EUBIROD project 242, 247, 248 Freestyle Navigator 114 G4 86, 116 G4 Platinum 86, 116 Gestational diabetes mellitus, see Pregnancy Glargine pregnancy use 19, 20 Global positioning system, continuous glucose remote monitoring 91, 92 Glucagon, artificial pancreas infusion 169, 179 GlucoDayS 114 Glucose regulation for intensive care patients, care unit 25 GlucoWatch2 Biographer 85 Glulisine, pregnancy use 19 Glycemic targets intensive versus nonintensive treatment 5, 6 pregnancy vascular event prevention 4, 5 Glycosylated hemoglobin A 1c, real-time continuous glucose monitoring pediatric studies Guardian monitor 84, 113, 114 Hospital patients blood glucose abnormalities 32, 33 critical care, see Intensive care unit discharge of patients with glucose abnormalities hyperglycemia management continuous subcutaneous insulin infusion 40 enteral nutrition patients 39, 40 glucocorticoid-receiving patients 38 guidelines 34 intravenous insulin transition to subcutaneous insulin 38 medical and surgical wards overview 34, 35 point of care glucose meters 26, 27, 40, 41, real-time continuous glucose monitoring 41 subcutaneous insulin dose 36 total parenteral nutrition patients 38, 39 hypoglycemia causes 42 prevention and management 42, 43 programs for glycemic control 45 Hyperglycemia Mitigation Module 173 Hypoglycemia continuous glucose monitoring in prevention 252, 253 studies 131, 132, 252 hospital patients causes 42 prevention and management 42, 43 low glucose suspension in prevention 152 real-time continuous glucose monitoring studies in pediatrics 103 self-monitoring of blood glucose driving risks 53, 54 overview 52 sensor-augmented pump 136, 148, 149 Insulin detemir, see Detemir Insulin pump, see Artificial pancreas, Continuous intraperitoneal insulin infusion, Continuous subcutaneous insulin infusion, Insulin therapy, see also Continuous subcutaneous insulin infusion, Multiple daily insulin, specific insulin formulations hospital patients, see Hospital patients, Intensive care unit pregnancy subcutaneous insulin dose in medical and surgical wards 36 Intensive care unit anti-insulin antibodies 204, 205 blood glucose abnormalities 23, 24 historical perspective 250, 251 hyperglycemia management central laboratory glucose measurement 27 computer-based protocols 25, 26 guidelines 24, 25 intravenous insulin transition to subcutaneous insulin 26 point of care glucose determination 26, 27, Subject Index

4 real-time continuous glucose monitoring 27, 28 Intensive treatment glycemic targets 5, 6 type 1 diabetes 6 9 ipro 84, 85 ipro2 85 Lispro, pregnancy use 19 Long-Term Sensor System 191 Low glucose suspend ASPIRE study 159, 160 pediatric diabetes 104, 105, predictive low glucose suspend 163, 164 rationale for hypoglycemia prevention 152 Veo system 160 LysPro N-protamine, pregnancy use 20 MEASURE trial 51 Menstruation, self-monitoring of blood glucose 55 MiniMed 83, 84, 113 Model predictive control artificial pancreas , closed-loop systems 159 care unit 25, 26 Multiple daily insulin comparison 7, 8 management in intensive and nonintensive treatment 8, 9 Neonatal diabetes, continuous subcutaneous insulin infusion 144 Neutral protamine Hagedorn enteral nutrition patient use 39, 40 historical perspective 7 pregnancy use 19, 20 New York City A 1c Registry 240 Nonintensive treatment glycemic targets 5, 6 type 1 diabetes 6 9 OmniPod 130 Otago Diabetes Register 239 Pediatric diabetes insulin pump, see Continuous subcutaneous insulin infusion, real-time continuous glucose monitoring, see Real-time continuous glucose monitoring Physical activity guidelines in diabetes 54 self-monitoring of blood glucose 54 sports, see Athletes PILGRIM study 164 Point of care glucose meters accuracy 65 blood sample factors in error historical perspective 63, 64 hospital patient use intensive care unit 26, 27, 74 medical and surgical wards 40, 41, strategies for use 75 needs 64 outliers hazards 68, 69 interfering substances 67, 68 recommendations regulatory agencies and standards technology and interfering factors 69, 70 trends 77 Pramlintide, artificial pancreas infusion 169 Predictive Low Glucose Management 163, 164 Pregnancy in type 1 diabetes patients 133 fetal risks of maternal diabetes 11 glycemic targets insulin therapy maternal metabolism 13, 14 prepregnancy counseling in diabetes 12 real-time continuous glucose monitoring self-monitoring of blood glucose 55, 56 sensor-augmented pump therapy 136, 137 Proportional-integral-derivative control artificial pancreas 171, 179, 183 closed-loop systems care unit 25 Real-time continuous glucose monitoring, see also Continuous glucose monitoring adult outpatients athletes with diabetes 120, 121 indications overview Subject Index 263

5 Real-time continuous glucose monitoring (cont.) pregnancy prospects 123 type 1 diabetes data analysis 93, 94 historical perspective 113, 114 intensive care unit 27, 28 mechanisms 41 medical and surgical ward patients 41, 42 pediatric patients glycosylated hemoglobin A 1c studies hypoglycemia studies 103 low-glucose threshold insulin suspend 104, 105 practical considerations professional versus real-time systems 82, 83, technical aspects accuracy 115, 116 calibration 114, 115 Registries, see Diabetes registers Self-monitoring of blood glucose adherence 252 continuous subcutaneous insulin infusion 54, 55 electronic diaries 312 historical perspective 47, 48 hypoglycemia driving risks 53, 54 overview 52 illness and infection 52, 53 lifestyle changes and testing needs 57 physical activity 54 prospects 58, 59 technological advancements 57, 58 type 1 diabetes frequency and demographics 49, 50 guidelines 49 starting and changing therapy women concerns breastfeeding 56 menstruation 55 preconception 55, 56 pregnancy 56, see also Artificial pancreas age of patients 134, 135 algorithms for calculating insulin delivery architecture of system 153, 154 cost-effectiveness 138 disadvantages 137 education of patients 134 frequency of sensing 135 glycemic control at baseline clinical studies 135 hypoglycemia 136 pregnancy 136, 137 quality of life 136 indications 138, 139 overview 133 pediatric diabetes evidence-based medicine 146, 147 guidelines 147 hypoglycemia 148, 149 limiting factors 147, 148 prospects 139 SevenD 114 Seven-Plus 85, 114 Sleep eating, continuous glucose monitoring 89 Sports, see Athletes, Physical activity STS-CGM system 85 SUPREME-DM project 238, 241 Swedish National Diabetes Register 241 Télédiab 1 study TELESAGE study 222, 223 Total parenteral nutrition, hyperglycemia management 38, 39 UK Prospective Diabetes Study blood glucose targets to prevent vascular events 4, 5 microangiopathy and glucose control effects 2 4 Veo 130, Subject Index

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE

More information

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing

More information

The Realities of Technology in Type 1 Diabetes

The Realities of Technology in Type 1 Diabetes The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments

More information

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,

More information

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set

More information

Updates in Diabetes Technology

Updates in Diabetes Technology Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin

More information

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center

More information

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA

More information

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid

More information

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for

More information

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization

More information

Does Technology helps adolescents with type 1 diabetes in fasting Ramadan?

Does Technology helps adolescents with type 1 diabetes in fasting Ramadan? Does Technology helps adolescents with type 1 diabetes in fasting Ramadan? Abdulmoein Al-Agha, FRCPCH Professor of Paediatric Endocrinology, King Abdulaziz University Hospital, http://aagha.kau.edu.sa

More information

Advances Towards the Bionic Pancreas.

Advances Towards the Bionic Pancreas. Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated

More information

UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication

UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication Citation for published version (APA): Kropff, J. (2017). The artificial pancreas: From logic to life General

More information

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history

More information

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing

More information

1. Continuous Glucose Monitoring

1. Continuous Glucose Monitoring 1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection

More information

Artificial Pancreas Device System (APDS)

Artificial Pancreas Device System (APDS) Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER

More information

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development

More information

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services. Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)

More information

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID FLUID Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent

More information

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin

More information

Diagnostics guidance Published: 12 February 2016 nice.org.uk/guidance/dg21

Diagnostics guidance Published: 12 February 2016 nice.org.uk/guidance/dg21 Integrated sensor-augmented pump therapy systems for managing blood glucose levels els in type 1 diabetes (the MiniMed Paradigm adigm Veo system and the Vibe and G4 PLATINUM CGM system) Diagnostics guidance

More information

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction

More information

Insulin Prior Authorization with optional Quantity Limit Program Summary

Insulin Prior Authorization with optional Quantity Limit Program Summary Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)

More information

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 05/24/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization

More information

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals

More information

Update on Diabetes Technology

Update on Diabetes Technology Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and

More information

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin

More information

MEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING SYSTEMS/ EXTERNAL INSULIN PUMP THERAPY FOR DIABETES EFFECTIVE DATE: 08/17/17

MEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING SYSTEMS/ EXTERNAL INSULIN PUMP THERAPY FOR DIABETES EFFECTIVE DATE: 08/17/17 MEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING PAGE: 1 OF: 11 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,

More information

CGM and Closing The Loop

CGM and Closing The Loop CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long

More information

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at

More information

Diabetes in Pregnancy

Diabetes in Pregnancy Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the

More information

Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets

Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets Devices Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets Accuracy Glucometers The ISO (International Organization for

More information

Name of Policy: Continuous or Intermittent Monitoring of Glucose in the Interstitial Fluid

Name of Policy: Continuous or Intermittent Monitoring of Glucose in the Interstitial Fluid Name of Policy: Continuous or Intermittent Monitoring of Glucose in the Interstitial Fluid Policy #: 038 Latest Review Date: December 2016 Category: DME Policy Grade: B Background/Definitions: As a general

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control

More information

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)

More information

Abbott FreeStyle Libre Pro System

Abbott FreeStyle Libre Pro System Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:

More information

JDRF Perspective on Closed Loop

JDRF Perspective on Closed Loop JDRF Perspective on Closed Loop Aaron J. Kowalski, Ph.D. Assistant Vice President Treatment Therapies Juvenile Diabetes Research Foundation International 1 Presenter Disclosure Aaron Kowalski Disclosed

More information

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 07/10/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization

More information

Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension

Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 2, 29 Mary Ann Liebert, Inc. DOI: 1.189/dia.28.32 Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension Bruce Buckingham,

More information

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will

More information

This certificate-level program is non-sponsored.

This certificate-level program is non-sponsored. Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.

More information

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A

More information

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors

More information

Diabetes Management: Current High Tech Innovations

Diabetes Management: Current High Tech Innovations Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:

More information

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. Waterproof to a depth

More information

Report Reference Guide

Report Reference Guide Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient

More information

The Artificial Pancreas

The Artificial Pancreas SAGLB.DIA.15.2.87(2). Approved October 215 The Artificial Pancreas For scientific and medical purposes only The pancreas responds to changes in blood glucose by releasing insulin (β cells) to lower blood

More information

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles

More information

The next five years in diabetes technology: closed-loop systems

The next five years in diabetes technology: closed-loop systems The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,

More information

INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. MORE TIME HERE TO USING

More information

Insulin therapy in gestational diabetes mellitus

Insulin therapy in gestational diabetes mellitus Insulin therapy in gestational diabetes mellitus October 15, 2015 Kyung-Soo Kim Division of Endocrinology & Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University Contents

More information

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization

More information

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.

More information

Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness

Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction

More information

DIAGNOSIS OF DIABETES NOW WHAT?

DIAGNOSIS OF DIABETES NOW WHAT? DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO

More information

Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm

Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Journal of Diabetes Science and Technology Volume 6, Issue 5, September 2012 Diabetes Technology Society ORIGINAL ARTICLE Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Fraser,

More information

Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting

Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting Disclaimers None Except products and software discussed are all proprietary, so if I mention a brand product it is because there is no other

More information

JDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director

JDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC

More information

Vishwanath Pattan Endocrinology Wyoming Medical Center

Vishwanath Pattan Endocrinology Wyoming Medical Center Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected

More information

The Current Environment of CGM Technologies. Barry H. Ginsberg, M.D., Ph.D.

The Current Environment of CGM Technologies. Barry H. Ginsberg, M.D., Ph.D. Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society SYMPOSIUM The Current Environment of CGM Technologies Introduction Barry H., M.D., Ph.D. This presentation

More information

Company Overview February 26, 2019

Company Overview February 26, 2019 Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,

More information

Sensor-augmented pump systems provide insulin delivery

Sensor-augmented pump systems provide insulin delivery DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c

More information

Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives

Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential

More information

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE The insulin pump Replaces injections Delivers insulin through a soft cannula

More information

COMPANY OVERVIEW. April 26, 2018

COMPANY OVERVIEW. April 26, 2018 COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,

More information

Continuous or Intermittent Glucose Monitoring in Interstitial Fluid

Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Policy Number: 1.01.20 Last Review: 9/2014 Origination: 11/2001 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City

More information

Objectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018

Objectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018 Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of

More information

Abbott FreeStyle Libre Pro System

Abbott FreeStyle Libre Pro System , the Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:

More information

VIRTUAL PATIENTS DERIVED FROM THE

VIRTUAL PATIENTS DERIVED FROM THE VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction

More information

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly

More information

Designed with your patients lives in mind

Designed with your patients lives in mind The Accu-Chek Insight diabetes therapy system Designed with your patients lives in mind With pre-filled insulin cartridge Designed for easy patient training The Accu-Chek Insight diabetes therapy system

More information

IPS Modern management of childhood diabetes mellitus

IPS Modern management of childhood diabetes mellitus Modern management of childhood diabetes mellitus Professor Philippe LYSY, MD PhD Pediatric endocrinology and diabetology Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain

More information

Continuous Glucose Monitoring

Continuous Glucose Monitoring Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are

More information

Making the Most of Continuous Glucose Monitoring

Making the Most of Continuous Glucose Monitoring Making the Most of Continuous Glucose Monitoring Gary Scheiner MS, CDE Owner & Clinical Director Integrated Diabetes Services LLC Wynnewood, PA AADE 2014 Diabetes Educator of the Year gary@integrateddiabetes.com

More information

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts

More information

Performance-powered. The OneTouch. Ping insulin pump and meter-remote.

Performance-powered. The OneTouch. Ping insulin pump and meter-remote. Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.

More information

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used

More information

Animas Vibe System World-class insulin pumping meets world-class CGM*

Animas Vibe System World-class insulin pumping meets world-class CGM* Animas Vibe System World-class insulin pumping meets world-class CGM* Fully integrated with Dexcom G4 PLATINUM CGM* *Continuous glucose monitoring. My Animas pump has really put me in the driver s seat

More information

Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous Glucose Sensors

Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous Glucose Sensors Journal of Diabetes Science and Technology Volume 2, Issue 5, September 2008 Diabetes Technology Society ORIGINAL ARTICLES Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous

More information

Diabetes Update 2017: Advancement in glucose monitoring & insulin Delivery

Diabetes Update 2017: Advancement in glucose monitoring & insulin Delivery Diabetes Update 2017: Advancement in glucose monitoring & insulin Delivery Abdulmoein Eid Al-Agha, MBBS, DCH, CABP, FRCPCH Professor of Pediatric Endocrinology, King Abdulaziz University Hospital Highlights

More information

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand

More information

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Continuous or Intermittent Monitoring

More information

COMPANY OVERVIEW. July 30, 2018

COMPANY OVERVIEW. July 30, 2018 COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,

More information

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest

More information

APEC Guidelines Gestational Diabetes Mellitus

APEC Guidelines Gestational Diabetes Mellitus Gestational diabetes mellitus (GDM) is defined as insulin resistance of variable severity with onset or first recognition during pregnancy. The prevalence of diabetes mellitus (DM) in the US is growing

More information

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid. Original Policy Date

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid. Original Policy Date MP 1.01.15 Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Medical Policy Section Durable Medical Equipment Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed

More information

Advances in Managing Diabetes in Youth. March 1, 2012

Advances in Managing Diabetes in Youth. March 1, 2012 Advances in Managing Diabetes in Youth March 1, 2012 Diabetes in Youth: An Update The Problem Increasing Incidence of Type 1 Diabetes The Cause New Information on an Enterovirus connection New Therapy

More information

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK) Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection

More information

Continuous Glucose Monitoring (CGM)

Continuous Glucose Monitoring (CGM) Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in

More information